HUTCHMED (China) earnings release, July 30, 2026
http://fasb.org/us-gaap/2025#EquityMethodInvesteeMember http://fasb.org/us-gaap/2025#RelatedPartyMember http://fasb.org/us-gaap/2025#RelatedPartyMember http://fasb.org/us-gaap/2025#RelatedPartyMember http://fasb.org/us-gaap/2025#RelatedPartyMember http://fasb.org/us-gaap/2025#EquityMethodInvesteeMember http://xbrl.sec.gov/country/2025#HK
Exhibit 99.1
HUTCHMED Reports 2026 Interim Results — China product sales recovery continues led by ELUNATE® and SULANDA® with over 40% growth each — — FRUZAQLA® ex-US sales driving growth – now approved or launched in 41 countries — — Strong progress in ATTCs, a source of novel drug candidates with broad therapeutic potential — Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 30, 2026:
HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:HCM; HKEX:13) today reports its financial results for the six months ended June 30, 2026 and provides updates on key clinical and commercial developments.
All amounts are expressed in US dollars unless otherwise stated. A glossary of abbreviations is on page 36.
Global sales growth driven by China rebound and FRUZAQLA® geographical expansion
Multiple first-in-class Antibody-Targeted Therapy Conjugate (ATTC) candidates in clinical trials
Regulatory and clinical achievements across late-stage clinical portfolio
¹
HUTCHMED to host results webcasts today at 8:00 a.m. EDT / 1:00 p.m. BST / 8:00 p.m. HKT in English on Thursday, July 30, 2026, and tomorrow at 8:30 a.m. HKT in Chinese (Putonghua) on Friday, July 31, 2026. After registration, investors may access the live webcast at www.hutch-med.com/event.
Dr Dan Eldar, Non-executive Chairman of HUTCHMED, said,
“HUTCHMED has a clear strategic focus: to build a globally competitive oncology portfolio anchored by differentiated innovation. This future is shaped by our global first-in-class Antibody-Targeted Therapy Conjugate (ATTC) novel payload platforms and other emerging large-molecule modalities. These give us multiple opportunities to pursue first-in-class or best-in-class assets, with potential to be used in combination with standard-of-care or newer medicines, in turn conferring front-line treatment prospects. As these programs advance, multinational partnerships – some presently under discussion – can provide important external validation, broaden development reach and accelerate access to major international markets. We will continue to invest in our world-class R&D organization and deploy our resources in areas where HUTCHMED can create significant impact on the lives of patients globally, harnessing the most advanced scientific modalities, while creating commercial and shareholder value.”
Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said,
“Strong in-market sales growth from ELUNATE® and SULANDA® in the first half reflects the impact of last year’s streamlining of our salesforce, enhancing productivity with more focused marketing strategies, as we structured our commercial organization to meet the changing China market regulatory guidelines for a sustainable future. We are accelerating ATTC development and strengthening discovery operations through expanding talent and AI capabilities. We are also pursuing business development discussions with multinational partners to expedite global development and commercialization of our most promising programs.”
Dr Weiguo Su, Chief Executive Officer (currently on leave of absence) and Chief Scientific Officer of HUTCHMED, said,
“The acceptance by the NMPA of the NDA filings for sovleplenib in ITP and wAIHA during the first half of 2026 reflects the strength of the clinical data package, supporting its potential for regulatory and commercial success. Sovleplenib once again attests to the importance of target selectivity, differentiating efficacy and toxicity profiles of our assets. Our ATTC drug candidates are guided by the same principles, designed to navigate our proprietary potent small-molecule targeted therapy payloads to tumor cells while sparing healthy tissues and decreasing side-effects. Pre-clinical data has shown encouraging tumor shrinkage as compared to standard-of-care treatments and emerging therapies recently launched or in development. With three highly novel molecules from two ATTC payload platforms progressing through or about to start first-in-human clinical development, and additional candidates advancing behind them, we are building a science-driven pipeline designed to translate differentiated biology into meaningful clinical benefit.”
²
2026 Interim Results & Business Updates
I. COMMERCIAL OPERATIONS
There was a strong rebound in China in-market sales, achieving $94.4 million in H1 2026, up 32% vs H1 2025 ($71.6 million) as our sales team continues to improve productivity. This contributed to total in-market sales for oncology products of $279.8 million in H1 2026 (H1-25: $234.4 million).
ELUNATE® in-market sales were up 41% to $60.8 million, successfully expanded NRDL coverage to include 2L EMC with pMMR in combination with sintilimab. It also renewed coverage in metastatic CRC for patients who have been previously treated with chemotherapy, and those who have previously received or are not suitable for receiving anti-VEGF or anti-EGFR (RAS wild-type).
SULANDA® in-market sales were up 45% to $18.4 million, driven by an update to Chinese Society of Clinical Oncology guidelines upgrading the usage for SULANDA® in neuroendocrine tumors to the highest Level I recommendation standard over competing SSA products. It also benefited from shifting marketing strategies to focus on key hospitals.
FRUZAQLA®... (truncated) boost global in-market sales to $185.4 million.
Total consolidated revenue for oncology products increased 23% to $121.4 million as compared to H1 2025, primarily due to strong in-market sales growth in ELUNATE® and SULANDA®.
Other Oncology/Immunology revenue, consisting of upfront, regulatory milestones, R&D services and licensing revenue was $40.9 million, including an $18.1 million milestone payment from Eli Lilly, triggered by China approval for 2L RCC. Other Ventures revenue, mainly from prescription drug distribution was $116.0 million, leading to total consolidated revenue of $278.3 million.
³
* FRUZAQLA®, ELUNATE® and ORPATHYS® mainly represent total sales to third parties as provided by Takeda,
Eli
Lilly and AstraZeneca, respectively.
** FRUZAQLA® represents manufacturing revenue and royalties paid by Takeda to HUTCHMED; ELUNATE® represents manufacturing revenue, promotion and marketing services revenue and royalties paid by
Eli
Lilly to HUTCHMED, and sales to other third parties invoiced by HUTCHMED; ORPATHYS® represents manufacturing revenue and royalties paid by AstraZeneca to HUTCHMED and sales to other third parties invoiced by HUTCHMED; SULANDA® and TAZVERIK® represent HUTCHMED’ s sales of the products to third parties.
*** Ipsen is the Marketing Authorization Holder for TAZVERIK®, for which HUTCHMED acts as domestic agent/licensee. In March 2026 Ipsen voluntarily withdrew TAZVERIK® from all Ipsen markets, effective immediately, following emerging safety data from the ongoing SYMPHONY
‑
1 trial.
⁴
II. 2026 REGULATORY UPDATES
III. 2026 LATE-STAGE CLINICAL DEVELOPMENT ACTIVITIES
Savolitinib (ORPATHYS® in China), a highly selective oral inhibitor of MET
Sovleplenib (HMPL-523), an investigative and highly selective oral inhibitor of Syk
Fanregratinib (HMPL-453), a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3
⁵
HMPL-760, a non-covalent, third generation BTK inhibitor, targeting wild-type and C481S-mutated BTK
IV. ANTIBODY-DRUG CONJUGATES RESEARCH & DEVELOPMENT
HMPL-A251, a first-in-class PI3K/PIKK-HER2
ATTC comprising of a highly selective and potent PI3K/PIKK inhibitor payload linked to a humanized anti-HER2 IgG1 antibody, via a cleavable linker
HMPL-
A
580, a first-in-class PI3K/PIKK-EGFR
ATTC comprising of a highly selective and potent PI3K/PIKK inhibitor payload linked to an anti-EGFR IgG1 antibody, via a cleavable linker
HMPL-A830 China/US INDs cleared
⁶
V. COLLABORATION UPDATES
ImageneBio is developing IMG-007, a non-T cell depleting, antibody-dependent cell-mediated cytotoxicity-silenced OX40 antagonist discovered by HUTCHMED
VI. OTHER VENTURES
VII. SUSTAINABILITY
The
2025 Sustainability Report was published in
April 2026 alongside the 2025 Annual Report. We have initiated a new target-setting cycle. A list of potential focus initiatives has been identified under our five sustainability pillars: Innovation, Climate Action, Human Capital, Access to Healthcare, and Ethics and Transparency. In 2026, we will develop this into a final list, including a roadmap for achievement and monitoring.
In 2026, our sustainability initiatives have continued to receive strong recognition. Most recently, our commitment was reflected in an upgraded AA rating by MSCI, recognizing HUTCHMED as a Leader, and placing us among the top 19% of pharmaceutical companies. For its second consecutive year, HUTCHMED was recognized as
Most Honored Company and ranked¹ st place in ESG in its sector by
Extel, formerly Institutional Investor Research, in its 16 th
Asia Executive Team Survey. It achieved top rankings across several areas – leading CEO, CFO, Investor Relations, ESG and Corporate Governance – earning the Most Honored Company designation. HUTCHMED was the only company to earn these designations in 2026 in All Asia (ex-Mainland China) Biopharmaceuticals.
⁷
Financial Highlights
Revenue for the six months ended June 30, 2026 was $
278.3 million compared to $
277.7 million for the six months ended June 30, 2025.
Net Expenses for the six months ended June 30, 2026 were $
262.4 million compared to $
239.0 million for the six months ended June 30, 2025.
⁸
Net Income attributable to HUTCHMED for the six months ended June 30, 2026 was $
15.9 million compared to $
455.0 million for the six months ended June 30, 2025.
Cash, Cash Equivalents and Short-Term Investments were $1,3
74.8 million as of June 30, 2026 compared to $1,36⁷.³ million as of December 31, 2025.
Foreign exchange impact:
The RMB appreciated against the US dollar on average by approximately 5% during the first half of 2026, which has impacted consolidated financial results as highlighted.
Use of Non-GAAP Financial Measures and Reconciliation – References in this announcement to adjusted Group net cash flows excluding financing activities and financial measures reported at CER are based on non-GAAP financial measures. Please see the “Use of Non-GAAP Financial Measures and Reconciliation” for further information relevant to the interpretation of these financial measures and reconciliations of these financial measures to the most comparable GAAP measures, respectively.
⁹
FINANCIAL GUIDANCE
HUTCHMED reiterates full year 2026 guidance for Oncology/Immunology consolidated revenue in the range of $330 million to $450 million. HUTCHMED will leverage its strong cash resources to accelerate ATTC global development and explore investment opportunities. Shareholders and investors should note that:
Financial Summary
Condensed Consolidated Balance Sheets Data
¹⁰
Condensed Consolidated Statements of Operations Data
¹¹
About HUTCHMED... (truncated)nd immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, and the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
Contacts
References
Unless the context requires otherwise, references in this announcement to the
“
Group,” the
“
Company,”
“
HUTCHMED,”
“
HUTCHMED Group,”
“ we,”
“ us,” and
“ our,” mean HUTCHMED (China) Limited and its subsidiaries unless otherwise stated or indicated by context.
¹²
Full release
Past Performance and Forward-Looking Statements
The performance and results of operations of the Group contained within this announcement are historical in nature, and past performance is no guarantee of future results of the Group. This announcement contains forward-looking statements within the meaning of the
“ safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words like
“ will”,
“ expects”,
“ anticipates”,
“ future”,
“ intends”,
“ plans”,
“ believes”,
“ estimates”,
“ pipeline”,
“ could”,
“ potential”,
“ first-in-class”,
“ best-in-class”,
“ designed to”,
“ objective”,
“ guidance”,
“ pursue”, or similar terms, or by express or implied discussions regarding potential drug candidates, potential indications for drug candidates or by discussions of strategy, plans, expectations or intentions. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that any of our drug candidates will be approved for sale in any market, that any approvals which have been obtained will continue to remain valid and effective in the future, or that the sales of products marketed or otherwise commercialized by HUTCHMED and/or its collaboration partners (collectively,
“
HUTCHMED’ s Products”) will achieve any particular revenue or net income levels. In particular, management’ s expectations could be affected by, among other things: unexpected regulatory actions or delays or government regulation generally; the uncertainties inherent in research and development, including the inability to me e t our key study assumptions regarding enrollment rates, timing and availability of subjects meeting a study’ s inclusion and exclusion criteria and funding requirements, changes to clinical protocols, unexpected adverse events or safety, quality or manufacturing issues; the delay or inability of a drug candidate to meet the primary or secondary endpoint of a study; the delay or inability of a drug candidate to obtain regulatory approval in different jurisdictions or the utilization, market acceptance and commercial success of HUTCHMED’ s Products after obtaining regulatory approval; discovery, development and/or commercialization of competing products and drug candidates that may be superior to, or more cost effective than, HUTCHMED’ s Products and drug candidates; the impact of studies (whether conducted by HUTCHMED or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties on the commercial success of HUTCHMED’ s Products and drug candidates in development; the ability of HUTCHMED to manufacture and manage supply chains, including various third party services, for multiple products and drug candidates; the availability and extent of reimbursement of HUTCHMED’ s Products from third-party payers, including private payer healthcare and insurance programs and government insurance programs; the costs of developing, producing and selling HUTCHMED’ s Products; the ability to obtain additional funding when needed; the ability to obtain and maintain protection of intellectual property for HUTCHMED’ s Products and drug candidates; the ability of HUTCHMED to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; global trends toward health care cost containment, including ongoing pricing pressures; uncertainties regarding actual or potential legal proceedings, including, among others, actual or potential product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes, and government investigations generally; and general economic and industry conditions, including uncertainties regarding the effects of the persistently weak economic and financial environment in many countries, uncertainties regarding future global exchange rates, uncertainties in global interest rates, and geopolitical relations, sanctions and tariffs. For further discussion of these and other risks, see HUTCHMED’ s filings with the US Securities and Exchange Commission, on AIM and on HKEX. HUTCHMED is providing the information in this announcement as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
¹³
In addition, this announcement contains statistical data and estimates that HUTCHMED obtained from industry publications and reports generated by third-party market research firms.... (truncated)ive undue weight to this data. Such data involves risks and uncertainties and are subject to change based on various factors, including those discussed above.
Inside Information
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018).
Medical Information
This announcement contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
Ends
¹⁴
OPERATIONS REVIEW
Oncology/Immunology
HUTCHMED discovers, develops, manufactures and markets novel targeted therapies and immunotherapies for the treatment of cancer and immunological diseases through a fully integrated team of approximately 860 scientists and staff, and an in-house oncology commercial organization of approximately 780 staff, based in Shanghai, Suzhou, Beijing and Hong Kong in China and New Jersey in the US.
All 13 clinical-stage drug candidates were in-house discovered and developed, three of which – fruquintinib, surufatinib and savolitinib – have been commercialized in China. Fruquintinib has also been approved and launched in major overseas markets, including the US, EU and Japan. Savolitinib is pending data readout from a global Phase III trial that, if positive, could support global NDA filings. A fourth drug candidate, sovleplenib, has two China NDAs under priority review, and a fifth drug candidate, fanregratinib, also has a China NDA under priority review. Our early-stage discovery and development is focused on our ATTC next-generation platform, with the first two candidates in global Phase I development.
RESEARCH & DEVELOPMENT
We possess a track record of discovery, clinical development, regulatory submissions and launch of innovative medicines. Our strategy is to establish a long-term business, by prioritizing late-stage and registrational studies in China and partnering outside of China. We plan to accelerate innovation through artificial intelligence (AI) integration, with a focus on key R&D stages to improve return on investment (ROI) and iterative learning. We plan to expedite the identification of high-potential drug candidates and reduce late-stage preclinical attrition.
Antibody-Targeted Therapy Conjugate (ATTC) Next Generation Technology Platforms
Unlike traditional ADCs, the toxin-based payload is replaced with a targeted small molecule in ATTCs. Thus, ATTCs have the potential to be administered in combination with chemotherapy or other targeted agents, which is particularly important in frontline settings. Another benefit of such design is to further optimize the strength of the small-molecule drugs, which may otherwise be limited by a narrow therapeutic window.
The first two ATTCs are based on a novel payload that targets the PI3K/AKT/mTOR (PAM) and PIKK pathways, critical intracellular networks involved in cell growth, survival, and division. Existing PAM-targeted small-molecule drugs face significant challenges, including on-target toxicities that restrict dosing, feedback loops that enable pathway reactivation, and insufficient tumor-specific delivery. HUTCHMED has designed a highly selective and potent PI3K/PIKK inhibitor linker-payload to overcome these challenges, exhibiting high selectivity, potency, and robust anti-tumor activity across a diverse panel of tumor cell lines. The payload potently inhibited PI3K and PIKK family kinases, with IC⁵⁰ ranging around 1 to 10 nM.
Preclinical data from the first ATTC candidate, HMPL-A251, was presented at AACR-NCI-EORTC in October 2025. HMPL-A251 is a first-in-class PI3K/PIKK payload linked to an anti-HER2 antibody via a cleavable linker. It demonstrated robust antitumor activities and bystander effect, with potent inhibition of HER2-positive tumor growth regardless of PAM pathway alterations, and inhibition in HER2-low, PAM-altered lines. It showed a strong response in cell lines resistant to trastuzumab deruxtecan, a HER2
‑ directed ADC. A global first-in-human trial initiated in December 2025 in patients with HER2-expressing solid tumors.
Preclinical data from the second ATTC candidate, HMPL-A580, was presented at AACR in April 2026. HMPL-A580 is a first-in-class PI3K/PIKK payload linked to an anti-EGFR antibody. HMPL-A580 showed a strong bystander effect when EGFR null cells were co-cultured with EGFR positive cells. In EGFRm NSCLC cell line, HMPL-A580 showed more tumor shrinkage than osimertinib. A global first-in-human trial initiated in March 2026 in patients with solid tumors.
¹⁵
IND was approved to advance a global first-in-human trial for the third ATTC candidate, HMPL-A830, which is based on a second novel ATTC payload. Preclinical data will be presented at a scientific conference.
Below is a summary update of the clinical trial progress of our investigational drug candidates. For more details about each trial, please refer to recent scientific publications.
Savolitinib (ORPATHYS® in China)
Mechanism of action
: savolitinib is an oral, potent and highly selective inhibitor of MET. The MET pathway functions abnormally through amplification, overexpression and mutations. The aberrant activation of MET is correlated with tumor growth, survival, invasion, metastasis, suppression of cell death and angiogenesis. MET aberrations may contribute to drug resistance in NSCLC, GC and CRC following anti-EGFR treatment.
Target indications... (truncated) MET amplified 2L NSCLC in combination with TAGRISSO®. In China, 30-40% of NSCLC patients are EGFRm (10-15% in the US). After 1L treatment, about 60% will develop resistance and progress to 2L, of which 1/3 are driven by MET. In June 2026, savolitinib expanded its indication to MET amplified 3L GC. There were estimated 359,000 people diagnosed with gastric cancer in China in 2022, according to Globocan. MET is an oncogenic driver occurring in 4-6% of GC. We are also developing savolitinib in MET overexpressed 1L and 2L NSCLC.
¹⁶
Clinical development
:
SACHI
China Phase III data was presented at ASCO 2025 in a late-breaking oral presentation, with mPFS of 6.9 months (HR 0.32) for 2L NSCLC patients who failed prior third-generation EGFR TKI. Further sub-group analysis published in
The Lancet in January 2026 showed mOS of 2
2.9 months (HR 0.3²) when excluding control chemotherapy group patients who received subsequent MET inhibitor.
SAFFRON global Phase III trial completed patient enrollment in October 2025, with topline results expected in H2 2026. Recruitment for the
SANOVO
China Phase III study was completed in August 2025, with results expected in H2 2026. Phase II single-arm, open-label China study for MET amplified 3L GC data was presented at ASCO 2026 and published in
Nature Medicine, with ORR at 32.3%, mPFS of 4.0 months and mOS of 6.9 months.
¹⁷
Commercial achievement
: Savolitinib for MET amplified 3L GC was approved in June 2026.
Fruquintinib (ELUNATE® in China, FRUZAQLA® outside of China)
Mechanism of action: fruquintinib is a selective oral inhibitor of VEGFR 1/2/3 kinases, designed to limit off-target kinase activity and improve drug exposure to achieve sustained target inhibition. Inhibition of the VEGFR can stop the growth of the vasculature around tumor and starve the tumor of nutrients and oxygen.
Target Indications
: fruquintinib was approved and launched for 3L CRC in China in 2018 and approved in the US in 2023. According to Globocan, there were 517,000 new CRC cases in China (160,000 in the US, 540,000 in Europe and 146,000 in Japan) in 2022. About 15-20% of cases progress to 3L. The second approved indication of fruquintinib was in combination with sintilimab for the treatment of 2L EMC with pMMR status. According to Globocan, there were 78,000 new EMC cases in China in 2022. About 15-20% of cases experience recurrence. Third approved indication was fruquintinib in combination with sintilimab for 2L RCC. According to Globocan, there were 74,000 new kidney cancer cases in China in 2022. About 90% are RCC and about 20-30% recur within the first five years.
¹⁸
Clinical development:
FRUSICA-2 China Phase III data was presented at ESMO Congress 2025 for 2L RCC in combination with sintilimab, showing mPFS of 22.2 months (HR 0.37, p<0.0001) and mDoR of 23.7 months. NMPA approved the indication in May 2026.
¹⁹
Commercial achievement
: for China, fruquintinib in combination with sintilimab in 2L EMC with pMMR is included in the NRDL effective January 1, 2026, enhancing patient access to this important therapeutic option. The average treatment duration in 2L EMC is almost twice that of 3L CRC. Outside China, our partner Takeda has obtained approval or launched fruquintinib in 41 markets to date.
Surufatinib (SULANDA® in China)
Mechanism of action
: surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFR and FGFR, both involved in tumor angiogenesis, and CSF-1R, which regulates tumor-associated macrophages, promoting immune response against tumor cells. Its dual mechanism of action may be suitable for combinations with other immunotherapies, such as PD-1 antibodies.
Target indications
: surufatinib was approved in China for non-pancreatic NETs in 2020 and for pancreatic NETs in 2021. There are approximately 40,000 new patients per year in China. Surufatinib is also being investigated in a Phase II/III study for 1L PDAC. PDAC is an aggressive form of cancer, representing over 90% of pancreatic cancer cases. According to Globocan, there were 119,000 new pancreatic cancer cases in China in 2022.
²⁰
Clinical development
: results from the Phase II part of a China Phase II/III study evaluating surufatinib combined with AiRuiKa®, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine for 1L PDAC were presented at ESMO Asia Congress 2025. The surufatinib combination demonstrated a mPFS of 7.20 months (HR 0.499, p=0.0407). OS data were still immature but showed a favorable trend (not reached vs 8.48 months, unstratified HR 0.555). The Phase III part of this study dosed first patient in December 2025, targeting enrollment of 400 patients with OS as the primary endpoint.
²¹
Updated clinical results of a Phase Ib/II IIT for 1L metastatic PDAC, in combination with AiRuiKa®, chemotherapy nab-paclitaxel and S-1, were presented at ASCO 2025 showing ORR of 51.1% (vs 24.4% in chemotherapy control arm) and mPFS of 7.9 months (vs. 5.4 months) (NCT05218889).
Commercial achievement
: surufatinib achieved second largest market share in NETs treatment during the third quarter of 2024, ahead of competitors SUTENT® and AFINITOR®.
Sovleplenib (HMPL-523)
Mechanism of action
: sovleplenib is a novel, selective, oral inhibitor targeting Syk. Syk is a kinase upstream to PI3Kδ and BTK within the B-cell signaling pathway and a target for modulating B-cell signaling. We believe it could deliver the same outcome as inhibitors of BTK and PI3Kδ. Its signaling processes not only affect cells of immune responses, but also affect tissue pathology in autoimmune, inflammatory and allergic diseases.
Target indications... (truncated) bruising. ITP is associated with fatigue (reported in up to 39% of adults with ITP) and impaired quality of life. As platelet destruction in ITP is mediated by Syk-dependent phagocytosis of FcγR-bound platelets, Syk inhibition is a promising approach to ITP management. According to IQVIA, China has 41,000 new ITP patients every year, on top of another
430,000 existing patients.
About half of ITP patients fail to have satisfactory results from currently approved treatments such as TPO/TPO-RAs.
AIHA is another autoimmune disorder where the immune system mistakenly attacks and destroys its own red blood cells, leading to anemia. The incidence of AIHA is estimated to be 0.8-3.0/100,000 adults per year with an estimated prevalence of 17 per 100,000 adults and a death rate of 8-11%. wAIHA is the most common form of AIHA, accounting for about 75-80% of all adult AIHA cases. China has 26,000 new wAIHA patients per year.
Clinical development
: the ESLIM-01 study showed that, in addition to its durable response in ITP patients, sovleplenib also improved significantly the quality of life in physical functioning and energy/fatigue ( p
<0.05). Most patients were heavily pretreated with a median of four prior lines of ІTP therapy, and a majority (72.6%) of the patients had received prior TPO/TPO-RA treatment. Post-hoc analysis of the study demonstrated consistent clinical benefits across ІTP patients regardless of prior lines of ІTP therapies or prior TPO/TPO-RA exposure.
Long-term efficacy and safety data from the same study was presented at ASH 2025. A total of 179 patients (All Sov) were treated with at least one dose of sovleplenib, including 126 patients who initially received sovleplenib and 53 patients who crossed over from placebo (P-Sov). The durable response rate was 51.4% and 43.4% for the two groups, and long-term durable response rate was 61.5% and 64.2%. For the All Sov group, median ratio of cumulative duration to overall treatment duration was 71.8% for platelet ≥ 50×10⁹
/L. Long-term treatment, with a median exposure of 86.3 weeks, did not increase safety risks and demonstrated low gastrointestinal toxicities.
²²
The ESLIM-02 study for wAIHA was presented at EHA 2026 Congress, with sovleplenib demonstrating a significantly higher durable response rate during weeks 5–24 compared to placebo (66% vs 15%, p<0.0001). During the 24-week double-blind treatment period, sovleplenib demonstrated superior efficacy across several key metrics; specifically, the overall response rate—defined as hemoglobin ≥100 g/L with an increase of ≥20 g/L from baseline without rescue therapy—was significantly increased (70% vs 22%, p<0.0001).
NMPA accepted resubmitted
NDA filing with priority review status and Breakthrough Designation for 2L ITP in February 2026, with additional data rolling in during the second half of 2026.
In April 2026, the
NMPA accepted the NDA filing with priority review status and Breakthrough Designation for 2L wAIHA.
The
C ompany is pursuing potential partnerships to continue overseas development.
Many Syk inhibitors have failed in the development stage due to their off-target toxicity as a result of lower kinase selectivity and possibly poor pharmacokinetic properties. Currently there is only one FDA-approved Syk inhibitor for ITP. There are FDA-approved competitors of different modalities targeting ITP, including a BTK inhibitor and a FcRn inhibitor. However, their 24-week durable response rates were either not disclosed or were significantly below that of sovleplenib. In May 2026, a FcRn inhibitor submitted NDA for 2L wAIHA in China. To date, there are no approved targeted therapies for wAIHA.
Fanregratinib (HMPL-453)
Mechanism of action
: fanregratinib is a novel, selective, oral inhibitor targeting FGFR 1/2/3. Activation of the FGFR pathway ultimately leads to increased cell proliferation, migration and survival. Aberrant FGFR signaling is associated with tumor growth, promotion of angiogenesis and resistance to anti-tumor therapies. Deregulation of the FGFR includes receptor amplification, activating mutations, gene fusions and receptor isoform switching.
Target indications
: ICC is one of the subtypes of primary bile duct cancer. In China, an estimated 61,900 newly diagnosed cases of ICC occurred in 2015, having increased by 9.2% per year between 2006 and 2015. Approximately 10-15% of ICC patients globally have tumors harboring FGFR2 fusions or rearrangements. ICC is an aggressive malignancy typically diagnosed at an advanced stage, with a 5-year OS below 10%; patients who progress after first-line chemotherapy have limited subsequent treatment options.
²³
Clinical development
: the pivotal Phase II registration study for ICC was presented at ESMO Gastrointestinal Cancers Congress 2026. This pivotal study is a single-arm, multi-center, open-label, Phase II registration clinical trial. The study has met its primary endpoint, demonstrating an IRC-assessed objective response rate of 42.5% (95% CI: 30.0%–53.6%). Furthermore, the mPFS was 6.9 months (95% CI: 4.1–8.2), while the mOS was 16.6 months (95% CI: 12.4–16.6). In December 2025, the NMPA accepted the NDA with priority review in 2L ICC.
Ranosidenib (HMPL-306)
Mechanism of action
: ranosidenib is a novel dual-inhibitor of IDH1 and IDH2 enzymes. When mutated, IDH creates 2-hydroxyglutarate, which alters genetic programming and prevents cells from maturing, causing activation of oncogenes and deactivation of tumor-suppressor genes. Targeting both IDH1 and IDH2 mutations benefits patients harboring either IDH mutation and addresses acquired resistance due to isoform switching.
Target indications... (truncated) achieve remission after treatment.
²⁴
Clinical development
: The RAPHAEL China Phase III study initiated in May 2024 on 2L R/R IDH1/2-mutant AML patients, comparing ranosidenib monotherapy versus chemotherapy. With OS as primary endpoint, we are targeting to recruit 320 patients.
One IDH1/2 dual inhibitor was approved in the US for IDH1/2-mutant Grade 2 astrocytoma or oligodendroglioma in August 2024. Similar indications were filed for NMPA approval in China in May 2026. To date, there are no IDH1/2 dual inhibitors approved or in late-stage development for AML.
²⁵
HMPL-
760
Mechanism of action
: HMPL-760 is a highly potent, selective, and reversible third-generation BTK inhibitor with long target engagement against BTK, including wild-type and C481S-mutated BTK. BTK is a key component of the B-cell receptor signaling pathway and is an important regulator of cell proliferation and cell survival in various lymphomas. The abnormal activation of B-cell receptor signaling is closely related to the development of B-cell type hematological cancers, which represent approximately 85% of all NHL cases. BTK is considered a validated target for drugs that aim to treat certain hematological cancers, however C481S mutation of BTK is a known resistance mechanism for first and second generation BTK inhibitors.
Target indications
: DLBCL is the most common form of aggressive non-Hodgkin lymphoma (“NHL”) worldwide, accounting for approximately 40% of all NHL cases in China. According to the Global Cancer Observatory, in 2022 approximately 81,000 new cases of NHL are estimated to have been diagnosed in China.
Clinical development
: A randomized, double-blind, positive controlled Phase III study was initiated in March 2026 on 2L R/R DLBCL patients, in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) versus placebo in combination with R-GemOx. With investigator-assessed PFS and OS as primary outcomes, we plan to enroll approximately 240 patients.
Collaborations with ImageneBio (Nasdaq:IMA) and Miragene Co
HUTCHMED discovered MAG-007 (non-covalent third-generation BTK, also known as IMG-004) and IMG-007 (non-T cell-depleting OX40 antagonist) for the treatment of multiple immunological diseases and has received shares as consideration for granting exclusive licenses to develop, manufacture and commercialize these two drug candidates worldwide. On a fully diluted basis, HUTCHMED holds approximately 9% in Miragene Co, which holds the license rights to MAG-007, and approximately 2% in ImageneBio (following a $30 million private placement by ImageneBio in April 2026), which holds the license rights to IMG-007.
²⁶
MANUFACTURING
Our new drug product facility in Shanghai has fully commenced operations and conducts small molecule drug product clinical and commercial supply manufacturing. In 2026, it passed FDA inspection with zero observations, and China NMPA pre-approval inspections of fanregratinib and sovleplenib. All small molecule drug product manufacturing can now be produced at this Shanghai facility, which can secure clinical and commercial supplies and bring significant production cost savings.
Commercial supplies of savolitinib and surufatinib were manufactured in the Shanghai facility, fully meeting commercial needs. Our Shanghai facility received FDA manufacturing approval for fruquintinib in January 2026. Currently we can deliver commercial batches of fruquintinib to the global and China markets from our own facility in Shanghai and a third-party CDMO site in Switzerland.
GMP production of our ATTC candidates has been conducted through collaboration with CDMOs. We have successfully completed production of several batches of investigational drug products of ATTC to supply the China and global clinical trials.
OTHER VENTURES
The Other Ventures is predominantly our Distribution Business (a 51%-held joint venture with Sinopharm Group Co. Ltd.) which provides services to third-party pharmaceutical companies in China. In the first half of 2026, Other Ventures consolidated revenue decreased to $116.0 million (H1-25: $134.2m).
Consolidated net income attributable to HUTCHMED from Other Ventures decreased to $3.8 million (H1-25: $24.0m) primarily due to the disposal of a 45% SHPL equity interest in April 2025.
Johnny Cheng
Acting Chief Executive Officer and Chief Financial Officer
July 30, 2026
²⁷
USE OF NON-GAAP FINANCIAL MEASURES AND
RECONCILIATION
In addition to financial information prepared in accordance with US GAAP, this announcement also contains certain non-GAAP financial measures based on management’s view of performance including:
Management uses such measures internally for planning and forecasting purposes and to measure HUTCHMED Group’s overall performance. We believe these adjusted financial measures provide useful and meaningful information to us and investors because they enhance investors’ understanding of the continuing operating performance of our business and facilitate the comparison of performance between past and future periods. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with US GAAP. Other companies may define these measures in different ways.
Adjusted Group net cash flows excluding financing activities:
We exclude deposits in and proceeds from short-term investments for the period and exclude the net cash generated from/(used in) financing activities for the period to derive our adjusted Group net cash flows excluding financing activities. We believe the presentation of adjusted Group net cash flows excluding financing activities provides useful and meaningful information about the change in our cash resources excluding those from financing activities which may present significant period-to-period differences.
CER:... (truncated)rent period’s performance at previous period’s foreign currency exchange rates. Because we have significant operations in China, the RMB to US dollar exchange rates used for translation may have a significant effect on our reported results. We believe the presentation at CER provides useful and meaningful information because it facilitates period-to-period comparisons of our results and increases the transparency of our underlying performance.
Reconciliation of GAAP change in net cash generated from
/(used in) operating activities to adjusted Group net cash flows excluding financing activities:
²⁸
Reconciliation of GAAP revenue and net income attributable to HUTCHMED to CER:
²⁹
GROUP CAPITAL RESOURCES
LIQUIDITY AND CAPITAL RESOURCES
To date, we have taken a multi-source approach to fund our operations, including through cash flows generated, dividend payments and divestment proceeds from our Oncology/Immunology and Other Ventures operations, service and milestone and upfront payments from our collaboration partners, bank borrowings, investments from third parties, proceeds from our listings on various stock exchanges and follow-on offerings.
We generated a net income attributable to HUTCHMED of $15.9 million for the six months ended June 30, 2026 (H1-25: $455.0m).
As of June 30, 2026, we had cash and cash equivalents and short-term investments of $1,374.8 million, unutilized bank facilities of $43.0 million and $94.5 million in bank borrowings.
Certain of our subsidiaries including those registered as wholly foreign-owned enterprises, and an equity investee in China, are required to set aside at least 10% of their after-tax profits to their non-distributable reserve funds until such reserves reach 50% of their registered capital. Profit appropriated to the reserve funds for our subsidiaries and equity investee incorporated in PRC was approximately nil and $2.1 million for the six months ended June 30, 2026 and 2025, respectively.
In addition, as a result of PRC regulations restricting dividend distributions from such reserve funds and from a company’s registered capital, our PRC subsidiaries are restricted in their ability to transfer a certain amount of their net assets to us as cash dividends, loans or advances. This restricted portion amounted to $2.3 million as of June 30, 2026.
CASH FLOW
Net Cash generated from
/
(used in) Operating Activities
Net cash generated from operating activities was $12.2 million for the six months ended June 30, 2026, compared to $72.9 million net cash used for the six months ended June 30, 2025. The net increase in cash generated of $85.1 million was mainly due to a capital gain tax payment of $59.5 million for the partial divestment of SHPL in April 2025 and $22.9 million improvement in working capital.³⁰
Net Cash generated from Investing Activities
Net cash generated from investing activities was $22.1 million for the six months ended June 30, 2026, compared to $17.6 million for the six months ended June 30, 2025. The net amounts generated for the six months ended June 30, 2026 were due to $27.7 million net withdrawals from short-term investments offset by $5.6 million for capital expenditures. The net amounts generated for the six months ended June 30, 2025 were due to gross proceeds from the partial divestment of SHPL of $608.5 million, offset by $571.7 million deposited into short-term investments along with $10.0 million regulatory approval milestone payment and $9.2 million for capital expenditures.
Net Cash (used in)
/ generated from Financing Activities
Net cash used in financing activities was $2.9 million for the six months ended June 30, 2026, compared to $9.3 million net cash generated for the six months ended June 30, 2025. The net amounts used for the six months ended June 30, 2026 were due to $2.9 million net repayments of bank borrowings. The net amounts generated for the six months ended June 30, 2025 were mainly due to $8.2 million drawn from bank borrowings to settle the capital expenditures for the Shanghai manufacturing site.
LOAN FACILITIES
In October 2021, our subsidiary entered into a 10-year fixed asset loan facility agreement with BOC for the provision of a secured credit facility in the amount of $112.3 million (RMB754.9 million) with an annual interest rate at the 5-year China LPR less 0.8% (which was supplemented in June 2022). This credit facility is guaranteed by the immediate holding company of the subsidiary, and secured by the underlying leasehold land and buildings (Shanghai manufacturing facility), and includes certain financial covenant requirements. For the six months ended June 30, 2026, $2.9 million (RMB19.6 million) was repaid and cannot be further drawn from the facility. The outstanding bank borrowings were $76.3 million (RMB513.3 million) as of June 30, 2026.
In October 2025, BOC extended a short-term unsecured working capital loan facility to our subsidiary in the amount of $29.7 million (RMB200.0 million) with an annual interest rate at the 1-year China LPR less 0.89%. This credit facility includes certain financial covenant requirements. As of June 30, 2026, $18.2 million (RMB122.1 million) was drawn from the loan facility.
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
The following table sets forth our contractual obligations as of June 30, 2026. Our purchase obligations relate to property, plant and equipment that are contracted for but not yet paid. Our lease obligations primarily comprise future aggregate minimum lease payments in respect of various factories, warehouse, offices and other assets under non-cancellable lease agreements.
³¹
FOREIGN EXCHANGE RISK... (truncated)ure to such risk, any significant fluctuation in the value of renminbi may adversely affect our cash flows, results of operations and financial condition in the future.
The value of the renminbi against the US dollar and other currencies may fluctuate and is affected by, among other things, changes in political, economic and market factors, including but not limited to monetary policies, interest rates, geopolitical relations, tariffs and economic performance. The conversion of renminbi into foreign currencies, including US dollars, has been based on rates set by the PBOC. If we decide to convert renminbi into US dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the US dollar against the renminbi would have a negative effect on the US dollar amounts available to us. On the other hand, if we need to convert US dollars into renminbi for business purposes, e.g. capital expenditures and working capital, appreciation of the renminbi against the US dollar would have a negative effect on the renminbi amounts we would receive from the conversion. In addition, for certain cash and bank balances deposited with banks in the PRC, if we decide to convert them into foreign currencies, they are subject to the rules and regulations of foreign exchange control promulgated by the PRC government.
CREDIT RISK
Substantially all of our bank deposits are in major financial institutions, which we believe are of high credit quality. We limit the amount of credit exposure to any single financial institution. We make periodic assessments of the recoverability of trade and other receivables and amounts due from related parties. Our historical experience in collection of receivables falls within the recorded allowances, and we believe that we have made adequate provision for uncollectible receivables.
INTEREST RATE RISK
We have no significant interest-bearing assets except for bank deposits. Our exposure to changes in interest rates is mainly attributable to our bank borrowings, which bear interest at floating interest rates and expose us to cash flow interest rate risk. We have not used any interest rate swaps to hedge our exposure to interest rate risk. We have performed sensitivity analysis for the effects on our results for the period from changes in interest rates on floating rate borrowings. The sensitivity to interest rates used is based on the market forecasts available at the end of the reporting period and under the economic environments in which we operate, with other variables held constant. According to the analysis, the impact on our results of a 1.0% interest rate shift would be a maximum increase/decrease of $0.5 million for the six months ended June 30, 2026.
OFF-BALANCE SHEET ARRANGEMENTS
We did not have during the years presented, and we do not currently have, any material off-balance sheet arrangements.
CONTINGENT LIABILITIES
Other than as disclosed in note 12 to the interim financial statements, the Group does not have any other significant commitments or contingent liabilities as at June 30, 2026.
GEARING RATIO
The gearing ratio of the Group, which was calculated by dividing total interest-bearing loans by total equity, was 7.4% as of June 30, 2026, remained unchanged as of December 31, 2025.
SIGNIFICANT INVESTMENTS HELD
We did not hold any significant investments in the equity of any companies as of June 30, 2026.³²
FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS
Note 12 to the interim financial statements discloses our capital commitment as of June 30, 2026.
MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES
During the six months ended June 30, 2026, we did not have any other material acquisitions and disposals of subsidiaries, associates and joint ventures.
PLEDGE OF ASSETS
Our 10-year fixed asset loan facility agreement with BOC is secured by the underlying leasehold land and buildings. The outstanding bank borrowing was $76.3 million (RMB513.3 million) as at June 30, 2026.
INFLATION
In recent years, China has not experienced significant inflation, and thus inflation has not had a material impact on our results of operations. According to the National Bureau of Statistics of China, the Consumer Price Index in China increased by 0.1% in 2024, increased by 0.8% in 2025 and increased by 1.0% in the first half of 2026. Although we have not been materially affected by inflation in the past, we can provide no assurance that we will not be affected in the future by higher rates of inflation in China.
INTERIM DIVIDEND
The Board does not recommend any interim dividend for the six months ended June 30, 2026.
³³
OTHER INFORMATION
CORPORATE STRATEGY
The primary objective of the Company is to be a leader in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The strategy of the Company is to leverage the highly specialized expertise of the drug discovery division, the Oncology/Immunology operations, to develop and expand the drug candidate portfolio of the Group for the global market, building on the first-mover advantage in the development and launch of novel cancer medicines in China, and engaging partners for late-stage development and commercialization outside China. This strategy is aligned with the Company’s culture of innovation and high engagement and empowerment of employees with a strong focus on reward and recognition. The Chairman’s Statement and the Operations Review contain discussions and analyses of the Group’s opportunities, performance and the basis on which the Group generates or preserves value over the longer term and the basis on which the Group will execute its strategy for delivering its objectives. The Group also focuses on sustainability and delivering business solutions to support the transition to a low-carbon economy. Further information on the sustainability initiatives of the Group and its key relationships with stakeholders can also be found in the standalone Sustainability Report of the Group.
SUSTAINABILITY
The key sustainability mission of the Group is to create long-term value for stakeholders by aligning its sustainability objectives to the strategic development of its businesses. The Board of Directors (“the Board”) has the overall responsibility to ensure that sustainability issues are integrated into the operations, strategy and long-term development of the Group. It provides oversight of the sustainability performance of the Group through closely monitoring key sustainability matters and performance indicators, along with trends, risks, and opportunities that may impact the business development of the Group. Supported by the Sustainability Committee, leadership team (including executives and senior management), and sustainability working groups, the Board oversees the management approach to sustainability matters and the formulation of sustainability strategies.
A standalone Sustainability Report of the Company for 2025 was published alongside the 2025 Annual Report in April 2026 and included further information on the Group’s sustainability initiatives and their performance. It further discussed the abovementioned sustainability mission and strategies, management approach, progress of goals and targets, material quantitative data, as well as policies and key initiatives of the Group. Over the course of 2026, the Group continues to engage its stakeholders to identify areas for improvement in these sustainability fronts.
HUMAN RESOURCES
As at June 30, 2026, the Group employed approximately 1,790 (June 30, 2025: ~1,780) full time staff members. Staff costs for the six months ended June 30, 2026, including directors’ emoluments, totaled $94.7 million (H1-25: $84.0 million).
The Group fully recognizes the importance of high-quality employees in sustaining market leadership. Salary and benefits are kept at competitive levels, while individual performance is rewarded within the general framework of the salary, bonus and incentive system of the Group, which is reviewed annually. Employees are provided with a wide range of benefits that include medical coverage, provident funds and retirement plans, and long-service awards. The Group stresses the importance of staff development and provides training programs on an ongoing basis. Employees are also encouraged to play an active role in community care activities.
PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES
During the period from January 1, 2026 to June 30, 2026, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the listed securities (including sale of treasury shares (within the meaning of the Hong Kong Listing Rules)) of the Company.³⁴
COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE
The Company strives to attain and maintain high standards of corporate governance best suited to the needs and interests of the Company and its subsidiaries as it believes that effective corporate governance framework is fundamental to promoting and safeguarding interests of shareholders and other stakeholders and enhancing shareholder value. Accordingly, the Company has adopted and applied corporate governance principles and practices that emphasize a quality Board, effective risk management and internal control systems, stringent disclosure practices, transparency and accountability as well as effective communication and engagement with shareholders and other stakeholders. It is, in addition, committed to continuously enhancing these standards and practices and inculcating a robust culture of compliance and ethical governance underlying the business operations and practices across the Group.
The Company has complied throughout the six months ended June 30, 2026 with all applicable code provisions of the Hong Kong Corporate Governance Code contained in Part 2 of Appendix C1 of the Hong Kong Listing Rules, as in force during the reporting period.
COMPLIANCE WITH THE SHARE DEALINGS CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS
The Board has adopted the Code on Dealings in Shares which is on terms no less exacting than the required standard set out in the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 of the Hong Kong Listing Rules as the code of conduct regulating Directors’ dealings in securities of the Company. In response to specific enquiries made, all Directors have confirmed that they have complied with the required standards set out in such code regarding their securities transactions throughout their tenure during the six months ended June 30, 2026.
REVIEW OF INTERIM UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The interim unaudited condensed consolidated financial statements of the Group for the six months ended June 30, 2026 have been reviewed by the auditor of the Company, PricewaterhouseCoopers, in accordance with Hong Kong Standard on Review Engagements 2410 – “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Hong Kong Institute of Certified Public Accountants for the Hong Kong filing. The interim unaudited condensed consolidated financial statements of the Group for the six months ended June 30, 2026 have also been reviewed by the Audit Committee of the Company.
IMPORTANT EVENTS AFTER THE REPORTING DATE
Save as disclosed above, no important events affecting the Company occurred since June 30, 2026 and up to the date of this announcement.
PUBLICATION OF INTERIM RESULTS AND INTERIM REPORT... (truncated)and the Company in August 2026.
³⁵
GLOSSARY
³⁶
³⁷
³⁸
INTERIM UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
HUTCHMED (CHINA) LIMITED
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN US$’
000, EXCEPT SHARE DATA)
The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.
³⁹
HUTCHMED (CHINA) LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED, IN US$’
000, EXCEPT SHARE AND PER SHARE DATA)
The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.
⁴⁰
HUTCHMED (CHINA) LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED, IN US$’
000)
The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.
⁴¹
HUTCHMED (CHINA) LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’
EQUITY
(UNAUDITED, IN US$’
000, EXCEPT SHARE DATA
IN’
000)
The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.
⁴²
HUTCHMED (CHINA) LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED, IN US$’
000)
The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.
⁴³
HUTCHMED (CHINA) LIMITED
NOTES TO THE INTERIM
UNAUDITED CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS
1. Organization and Nature of Business
HUTCHMED (China) Limited (the “Company”) and its subsidiaries (together the “Group”) are principally engaged in researching, developing, manufacturing and marketing pharmaceutical products. The Group has research and development facilities and manufacturing plants in the People’s Republic of China (the “PRC”) and sells its products mainly in the PRC, including Hong Kong and Macau. In addition, the Group has established international operations in the United States of America (the “US”) and Europe.
The Company’s ordinary shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited and the AIM market of the London Stock Exchange, and its American depositary shares (“ADS”) are traded on the Nasdaq Global Select Market (“NASDAQ”).
Liquidity
As at June 30, 2026, the Group had accumulated losses of US$
362,715,000 primarily due to its spending in drug research and development activities. The Group regularly monitors current and expected liquidity requirements to ensure that it maintains sufficient cash balances and adequate credit facilities to meet its liquidity requirements in the short and long term. As at June 30, 2026, the Group had cash and cash equivalents of US$
106,557,000, short-term investments of US$
1,268,260,000 and unutilized bank borrowing facilities of US$
43,038,000. Short-term investments are comprised of bank deposits maturing over three months.
Based on the Group’s operating and development plan, the existing cash and cash equivalents, short-term investments and unutilized bank borrowing facilities are considered to be sufficient to meet the cash requirements to fund planned operations and other commitments for at least the next twelve months from the issuance date of the interim unaudited condensed consolidated financial statements.
². Summary of Significant Accounting Policies
Basis of Presentation
The interim unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the US (“US GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period.
The comparative year-end condensed balance sheet data was derived from the annual audited consolidated financial statements, but is condensed to the same degree as the interim condensed balance sheet data.
The interim unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users have read or have access to the annual audited consolidated financial statements for the preceding fiscal year.
The preparation of interim unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the interim unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period.⁴⁴
Recent Accounting Pronouncements
Amendments that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Group’s condensed consolidated financial statements.
³. Cash and Cash Equivalents and Short-term Investments
Note: The maturities for short-term investments ranged from⁹² to
185 days and⁹¹ to
186 days for the six months ended June 30, 2026 and the year ended December 31, 2025 respectively.... (truncated) Cash and cash equivalents and short-term investments were denominated in the following currencies:
⁴⁵
4. Accounts Receivable
Accounts receivable from contracts with customers consisted of the following:
Substantially all accounts receivable are denominated in RMB, US$ and HK$ and are due within one year from the end of the reporting periods. The carrying values of accounts receivable approximate their fair values due to their short-term maturities.
An aging analysis for accounts receivable—third parties based on the relevant invoice dates is as follows:
Movements on the allowance for credit losses:
⁴⁶
5. Other Receivables, Prepayments and Deposits
Other receivables, prepayments and deposits consisted of the following:
No allowance for credit losses has been made for other receivables, prepayments and deposits for the six months ended June 30, 2026 and the year ended December 31, 2025.
⁶. Inventories
Inventories, net of provision for excess and obsolete inventories, consisted of the following:
⁷. Investment in Equity Investees
Investment in equity investees mainly consisted of the following:
Notes:
⁴⁷
8. Accounts Payable
Substantially all accounts payable are denominated in HK$, RMB and US$ and due within one year from the end of the reporting period. The carrying values of accounts payable approximate their fair values due to their short-term maturities.
An aging analysis for accounts payable - third parties based on the relevant invoice dates is as follows:
⁹. Other Payables and Accruals
Other payables and accruals consisted of the following:
⁴⁸
¹⁰. Bank Borrowings
Bank borrowings consisted of the following:
The weighted average interest rate for outstanding bank borrowings for the six months ended June 30, 2026 and the year ended December 31, 2025 was
2.58
% per annum and
2.73
% per annum respectively. The carrying amounts of the Group’s outstanding bank borrowings as at June 30, 2026 and December 31, 2025 were denominated in RMB.
(i)
Short-term working capital loan facility
In October 2025, a bank extended a short-term unsecured working capital loan facility to a subsidiary in the amount of US$
29,744,000
(RMB
200,000,000) with an annual interest rate at the 1-year China Loan Prime Rate (“LPR”) less
0.89
%. As at June 30, 2026 and December 31, 2025, US$
18,165,000
(RMB
122,142,000) and US$
20,228,000
(RMB
142,142,000) were drawn from the facility respectively.
(ii) 10-year fixed asset loan facility
In October 2021, a subsidiary entered into a
10-year fixed asset loan facility agreement with the bank for the provision of a secured credit facility in the amount of US$
112,264,000
(RMB
754,880,000) with an annual interest rate at the 5-year China LPR less
0.8
% (which was supplemented in June 2022). This credit facility is guaranteed by the immediate holding company of the subsidiary and secured by the underlying leasehold land and buildings (Shanghai manufacturing facility). For the six months ended June 30, 2026 and the year ended December 31, 2025, US$
2,899,000
(RMB
19,610,000) and US$
1,479,000
(RMB
10,390,000) were repaid respectively, and cannot be further drawn from the facility. The outstanding bank borrowings were US$
76,343,000
(RMB
513,342,000) and US$
72,932,000
(RMB
512,496,000) as at June 30, 2026 and December 31, 2025 respectively.
The Group’s bank borrowings are repayable as from the dates indicated as follows:
As at June 30, 2026 and December 31, 2025, the Group had aggregate unutilized bank borrowing facilities of US$
43,038,000 and US$
41,248,000 respectively.
⁴⁹
11. Other Non-current Liabilities
Other non-current liabilities consisted of the following:
12. Commitments and Contingencies
The Group had the following capital commitments:
The Group does not have any other significant commitments or contingencies.¹³. Share-based Compensation
(i) Share-based Compensation of the Company
The Company conditionally adopted a share option scheme on April 24, 2015 (as amended on April 27, 2020) and such scheme has a term of
10 years. It expired in May 2026 and no further share options can be granted. A new share option scheme was adopted on May 12, 2026 (the “HUTCHMED Share Option Scheme”). Pursuant to the HUTCHMED Share Option Scheme, the Board of Directors of the Company may, at its discretion, offer any employees and directors (including Executive and Non-executive Directors but excluding Independent Non-executive Directors) of the Company, holding companies of the Company and any of their subsidiaries or affiliates, and subsidiaries or affiliates of the Company share options to subscribe for shares of the Company.
As at June 30, 2026, the aggregate number of shares issuable under the HUTCHMED Share Option Scheme was
43,616,756 ordinary shares and the aggregate number of shares issuable under the prior share option scheme which expired in 2026 was
23,093,022 ordinary shares. The Company will issue new shares for share options exercised. Additionally, the number of shares authorized but unissued was
627,664,880 ordinary shares.
Share options granted are generally subject to a four-year vesting schedule, depending on the nature and the purpose of the grant. Share options subject to the four-year vesting schedule, in general, vest²⁵
% upon the first anniversary of the vesting commencement date as defined in the grant letter, and²⁵
% every subsequent year. However, certain share option grants may have a different vesting schedule as approved by the Board of Directors of the Company. No outstanding share options will be exercisable or subject to vesting after the expiry of a maximum of ten years from the date of grant.⁵⁰
A summary of the Company’s share option activity and related information is as follows:
... (truncated)ercisable is subject to certain performance targets based on a market condition covering the
3-year period from 2025 to 2027 which has been reflected in estimating the grant date fair value using the Monte Carlo simulation model. The grant date fair value of such award is US$
1.17 per share. Vesting of such award will occur around March 2028 if the performance targets are met.
The following table summarizes the Company’s share options exercised:
The Group recognizes compensation expense on a graded vesting approach over the requisite service period. The following table presents share-based compensation expense included in the Group’s condensed consolidated statements of operations:
⁵¹
As at June 30, 2026, the total unrecognized compensation cost was US$
1,681,000, and will be recognized on a graded vesting approach over the weighted average remaining service period of
1.40 years.
(ii)
LTIP
The Company grants awards under the LTIP to participating directors and employees, giving them a conditional right to receive ordinary shares of the Company or the equivalent ADS (collectively the “Awarded Shares”) to be purchased by the Trustee up to a cash amount excluding any cash elected payments. Vesting will depend upon continued employment of the award holder with the Group and will otherwise be at the discretion of the Board of Directors of the Company. Additionally, some awards are subject to change based on annual performance targets prior to their determination date.
LTIP awards prior to the determination date
Performance targets vary by award, and may include targets for shareholder returns, revenue and profitability. As the extent of achievement of the performance targets is uncertain prior to the determination date, a probability based on management’s assessment on the achievement of the performance target has been assigned to calculate the amount to be recognized as an expense over the requisite period with a corresponding entry to liability.
LTIP awards after the determination date
Upon the determination date, based on the actual achievement of performance targets, the amount previously recorded in the liability will be adjusted through share-based compensation expense. The Company will pay a determined monetary amount, up to the maximum cash amount based on the actual achievement of the performance target specified in the award, to the Trustee to purchase the Awarded Shares. Any cumulative compensation expense previously recognized as a liability will be transferred to additional paid-in capital.
The Trustee has been set up solely for the purpose of purchasing and holding the Awarded Shares during the vesting period on behalf of the Company using funds provided by the Company. On the determination date, if any, the Company will determine the cash amount, based on the actual achievement of each annual performance target, for the Trustee to purchase the Awarded Shares. The Awarded Shares will then be held by the Trustee until they are vested.
⁵²
The Trustee’s assets include treasury shares and funds for additional treasury shares, trustee fees and expenses. The number of treasury shares (in ordinary shares equivalent) held by the Trustee were as follows:
For the six months ended June 30, 2026 and 2025, US$
351,000 and US$
2,086,000 of the LTIP awards were forfeited respectively based on the determined or estimated monetary amount as at the forfeiture date.
The following table presents the share-based compensation expenses recognized under the LTIP awards:
For the six months ended June 30, 2026 and 2025, US$
1,157,000 and US$
751,000 were reclassified from liability to additional paid-in capital respectively upon LTIP awards reaching the determination date. As at June 30, 2026 and December 31, 2025, US$
143,000 and US$
2,406,000 were recorded in liabilities respectively.
As at June 30, 2026, the total unrecognized compensation cost was approximately US$
3,439,000, which considers expected performance targets and the amounts expected to vest, and will be recognized over the requisite periods.
⁵³
14. Revenue
The following table presents revenue disaggregated by contract type:
⁵⁴
The following table presents liability balances from contracts with customers:
Notes:
⁵⁵
¹⁵.
Research and Development Expenses
Research and development expenses are summarized as follows:
Research and development expenses include expenditures for collaborative arrangements under ASC 808 to evaluate the combination of the Group’s drug compounds with the collaboration partners’ drug compounds. For the six months ended June 30, 2026 and 2025, the Group has incurred US$
6.3 million and US$
3.2 million respectively, related to such collaborative arrangements.
Note: Personnel compensation and related costs mainly included clinical and regulatory, discovery, chemistry, manufacturing and controls functions. A portion of these costs are absorbed in inventory costs based on commercial production and are not included in research and development expenses.
16. Gain on Divestment of an Equity Investee
On April 25, 2025, the Group completed the divestment of an aggregate⁴⁵
% equity interest out of⁵⁰
% in SHPL to third parties for cash consideration of US$
608.5 million (RMB
4.5 billion), including an aggregate³⁵
% equity interest to two China-based private-equity funds (“PE Buyers”) and¹⁰
% equity interest to the parent company of the existing⁵⁰
% SHPL joint venture partner. In regard to the sales and purchase agreements with the PE Buyers, they include a profit guarantee clause with contingent payments capped at US$
103.5 million (RMB
696 million) based on growth targets of SHPL’s net income after tax for the
3 years up to 2027. As of the date of disposal, the Group recognized a provision for profit guarantee of US$
75.8... (truncated)une 30, 2026 and December 31, 2025, the provision for profit guarantee balance were US$
83.6 million and US$
80.0 million respectively.
The Group has the rights to nominate one director out of seven on SHPL’s board of directors, thus the Group continues to have significant influence and accounts for its remaining⁵
% equity interest in SHPL using the equity method of accounting.
⁵⁶
For the six months ended June 30, 2025, the gain on divestment of an equity investee was as follows:
17. Significant Transactions with Related Parties and Non-Controlling Shareholders of Subsidiaries
The Group has the following significant transactions with related parties and non-controlling shareholders of subsidiaries, which were carried out in the normal course of business at terms determined and agreed by the relevant parties:
⁵⁷
Notes:
⁵⁸
¹⁸. Income Taxes
Note: Others mainly include US and HK tax jurisdictions.
⁵⁹
After the prospective adoption of ASU 2023-09, the reconciliation of the Group’s reported income tax expense to the theoretical tax amount that would arise using the statutory tax rate of the Company against the Group’s income before income taxes and equity in earnings of equity investees is set out below. The statutory tax rate of HK is applied given that the Company satisfies the criteria for HK tax residency.
⁶⁰
The reconciliation of the Group’s reported income tax expense to the theoretical tax amount that would arise using the tax rates of the Company against the Group’s income before income taxes and equity in earnings of an equity investee is as follows:
19. Earnings Per Share
(i) Basic earnings per share
Basic earnings per share is calculated by dividing the net income attributable to the Company by the weighted average number of outstanding ordinary shares in issue during the period. Treasury shares held by the Trustee are excluded from the weighted average number of outstanding ordinary shares in issue for purposes of calculating basic earnings per share.
⁶¹
(ii) Diluted earnings per share
Diluted earnings per share is calculated by dividing the net income attributable to the Company by the weighted average number of outstanding ordinary shares in issue and dilutive ordinary share equivalents outstanding during the period. Dilutive ordinary share equivalents include shares issuable upon the exercise or settlement of share options and LTIP awards issued by the Company using the treasury stock method.
²⁰. Segment Reporting
The Group’s operating segments are Oncology/Immunology and Other Ventures.
Oncology/Immunology focuses on discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Oncology/Immunology is further segregated into two core business areas:
Other Ventures comprises other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
In general, revenue, cost of revenue and operating expenses are directly attributable, or are allocated, to each segment. The Company allocates costs and expenses that are not directly attributable to a specific segment mainly on the basis of headcount or usage, depending on the nature of the relevant costs and expenses. The Company does not allocate assets to its segments as the CODM does not evaluate the performance of segments using asset information.
⁶²
The performance of the reportable segments is assessed based on segment net income/(loss) attributable to the Company.
(i)
Segment information:
Note: On March 9, 2026, Ipsen S.A. announced the voluntary withdrawal of tazemetostat globally and the Group discontinued all tazemetostat commercial and development activities. Accordingly, the Group has fully impaired the related intangible asset and was included in Other income, net in the condensed consolidated statements of operations.
⁶³
⁶⁴
Unallocated mainly represent corporate expenses which include corporate administrative costs, corporate employee benefit expenses and the relevant share-based compensation expenses, net of interest income, as well as other one-off items. Unallocated assets mainly comprise cash and cash equivalents and short-term investments.
(ii)
Geographic information:
(iii)
Other information:
A summary of customers which accounted for over 10% of the Group’s revenue for the six months ended June 30, 2026 and 2025 is as follows:
Customer A and B are included in Oncology/Immunology.
⁶⁵
²¹. Note to Condensed Consolidated Statements of Cash Flows
Reconciliation of net income for the period to net cash generated from/(used in) operating activities:
⁶⁶
22.
Litigation
From time to time, the Group may become involved in litigation relating to claims arising from the ordinary course of business. The Group believes that there are currently no claims or actions pending against the Group, the ultimate disposition of which could have a probable material adverse effect on the Group’s financial position, results of operations or cash flows. However, litigation is subject to inherent uncertainties and the Group’s view of these matters may change in the future. When an unfavorable outcome occurs, there exists the possibility of a material adverse impact on the Group’s financial position, results of operations or cash flows for the periods in which the unfavorable outcome occurs, and potentially in future periods.... (truncated)o seek damages. On October 21, 2021 (and a decision on costs and interest in December 2021), the Group was awarded an amount of US$
37.7 million (RMB
253.2 million) with interest of
5.5
% per annum from the date of the award until payment and recovery of costs of approximately US$
2.2 million (collectively the “Award”). On June 27, 2022, Luye provided the Group a bank guarantee of up to RMB
286.0 million (subsequently updated to RMB
335.2 million with validity extended to June 25, 2027) to cover the Award amounts, pending the outcome of an application by Luye to the High Court of Hong Kong to set aside the Award and subsequent appeals. On July 26, 2022, Luye’s application to set aside the Award was dismissed by the High Court with costs awarded in favor of the Group. On October 7, 2022, Luye filed a Notice of Appeal to the Court of Appeal and on June 6, 2023, the Court of Appeal heard Luye’s application to set aside the Award. On May 8, 2026, Luye’s application to set aside the Award was dismissed again, this time by the Court of Appeal with costs in favor of the Group. On June 5, 2026, Luye further applied to the Court of Appeal for leave to appeal to the Court of Final Appeal with the outcome pending. The legal proceedings are ongoing and as no Award amounts have been received as at the issuance date of these interim unaudited condensed consolidated financial statements, no Award amounts have been recognized and no adjustment has been made to Seroquel-related balances as at June 30, 2026. Such Seroquel-related balances include accounts receivable, accounts payable and other payables of US$
1.1 million, US$
0.9 million and US$
1.2 million respectively.
²³.
Subsequent Events
The Group evaluated subsequent events through July 30, 2026, which is the date when the interim unaudited condensed consolidated financial statements were issued.
⁶⁷